Search clinical trials for: Detemir or Glargine

Total 6281 results

Eli Lilly and Company

Completed

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Type 2 Diabetes

United States
Vanderbilt University Medical Center
Sanofi

Completed

Characteristics of Glargine in Type 2 Diabetics

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Diabetes Mellitus, Type 2 | Diabetes

United States
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus (EDITION JP I)

Type 1 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, United States, Australia, Hungary, Poland, Romania, Spain
Sanofi

Completed

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients (TITRATION)

Type 2 Diabetes Mellitus

Canada
Sanofi

Completed

Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes (AFICIONADO)

Diabetes Mellitus, Type 2

Argentina
GWT-TUD GmbH

Completed

Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects (GLORY)

Type 2 Diabetes

Germany
Sanofi

Completed

Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Medical University of South Carolina

Completed

IV Insulin Protocol in Diabetes and Renal Transplantation

Hyperglycemia | Diabetes | Kidney Transplantation

United States
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Indonesia University

Completed

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus

Indonesia
Sanofi

Completed

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Novo Nordisk A/S

Terminated

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes (3L)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, France
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovenia
Changhua Christian Hospital

Recruiting

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

Diabetic Ketoacidosis | Hyperglycaemic Crisis in Diabetes Mellitus | Hyperglycaemic Hyperosmolar Nonketotic Syndrome

Taiwan
University Hospital Tuebingen

Terminated

Effects of Insulin Glargine and Lixisenatide on the Brain (Lixibrain01)

Diabetes Mellitus, Type 2

Germany
RISE Study Group
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

RISE Adult Medication Study (RISE Adult)

Type 2 Diabetes | Prediabetes

United States
Ain Shams University

Recruiting

Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

Chronic Kidney Diseases

Egypt
prof dr Pieter Gillard
University Hospital, Antwerp; Onze Lieve Vrouw Hospital

Completed

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL (FUTURE-GLARE)

Type 1 Diabetes

Belgium
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Health Care for Type 1 Diabetes in Developing World

Type 1 Diabetes

Rwanda
Sanofi

Completed

Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

Insulin Glargine During and After the Period of Fasting in Ramadan

Diabetes Mellitus, Type 2
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

Type 2 Diabetes Mellitus

United States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

India, Italy, United Kingdom, Finland, Japan, Argentina, Macedonia, The Former Yugoslav Republic of, Brazil
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Sanofi

Terminated

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Type 1 Diabetes Mellitus

United States, Canada
Mylan Inc.
Mylan GmbH

Completed

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2) (INSTRIDE 2)

Type 2 Diabetes

United States, Jordan, Korea, Republic of, Slovakia, South Africa, Taiwan
Eli Lilly and Company

Completed

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Diabetes Mellitus, Type 1 | Healthy Volunteers

United States
Sanofi

Completed

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Russian Federation, Denmark, Sweden, Macedonia, The Former Yugoslav Republic of, Norway, Croatia, France, Belgium, Slovakia
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications (SENIOR)

Type 2 Diabetes Mellitus

United States, Australia, Spain, Korea, Republic of, Hungary, Mexico, Italy, Poland, Argentina, Canada, Colombia, France, Germany, Japan, Peru, Romania, Sweden, United Kingdom
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Sanofi

Completed

Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL (TOP1)

Type I Diabetes Mellitus

Brazil
Shenzhen Second People's Hospital

Unknown

Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin

Type 2 Diabetes
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Sanofi

Completed

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment (Transition II)

Diabetes Mellitus, Type 2

France
Xijing Hospital

Unknown

A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

Type 2 Diabetes Mellitus

China
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine) (GALATEE)

Type 2 Diabetes

France
Skane University Hospital
Medical Research Council; Skane County Council Research & Development Foundation

Completed

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

Type 2 Diabetes | Secondary Drug Failure

Sweden
Eli Lilly and Company

Completed

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
Biodel

Completed

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Diabetes Mellitus

United States

3

Subscribe